Clinical Trials Using Talazoparib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talazoparib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-20 of 20
  • I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 15 locations

  • Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

    Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
    Location: 16 locations

  • Javelin BRCA / ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

    Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
    Location: 11 locations

  • Talazoparib For Neoadjuvant Treatment Of Germline Brca1 / 2 Mutation Patients With Early Triple-negative Breast Cancer

    A PHASE 2, NON RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1 / 2 MUTATION PATIENTS WITH EARLY TRIPLE NEGATIVE BREAST CANCER
    Location: 11 locations

  • An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

    This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
    Location: 6 locations

  • Avelumab and Talazoparib in Treating Patients with MSS, MSI-H, and POLE-Mutated Recurrent or Persistent Endometrial Cancer

    This phase II trial studies how well avelumab and talazoparib work in treating patients with microsatellite stable (MSS), high frequency microsatellite instability (MSI-H), and polymerase e (POLE)-mutated endometrial cancer that has spread to other places in the body or that does not go to remission despite treatment. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avelumab and talazoparib may work better in treating MSS endometrial cancer compared to avelumab alone.
    Location: 5 locations

  • Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

    This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced / metastatic solid tumors.
    Location: 5 locations

  • A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

    This Phase 1b / 2 study will examine the effects of the study drugs, avelumab and binimetinib given together (doublet) and in combination with talazoparib (triplet), in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects.
    Location: 4 locations

  • A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

    The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and / or abiraterone acetate / prednisone).
    Location: 5 locations

  • Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

    This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
    Location: 5 locations

  • Open-Label Extension and Safety Study of Talazoparib

    This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.
    Location: 3 locations

  • Decitabine and Talazoparib in Treating Patients with Untreated Relapsed, or Refractory Acute Myeloid Leukemia

    This phase I / II trial studies best dose and side effects of decitabine and talazoparib and how well they work in treating patients with acute myeloid leukemia that is untreated, has come back, or does not respond to treatment. Decitabine and talazoparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Talazoparib and Gedatolisib in Treating Patients with Advanced Triple Negative or BRCA1 / 2 Positive, HER2 Negative Breast Cancer

    This phase I / II trial studies the best dose of talazoparib when given together with gedatolisib and to see how well they work in treating patients with triple negative or BRCA1 / 2 positive, HER2 negative breast cancer that has spread to other places in the body and cannot be removed by surgery. Talazoparib and gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Talazoparib blocks an enzyme called PARP. Talazoparib causes cancer cells to die by breaking the tumor DNA and then stopping the tumor from repairing the damaged DNA. Gedatolisib blocks two receptors called PI3K and mTOR. By blocking these pathways, gedatolisib may cause cancer cells to die and stop growing.
    Location: 4 locations

  • Talazoparib and Low-Dose Temozolomide in Treating Participants with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

    This phase II trial studies how effective talazoparib and temozolomide are for treating participants with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating participants with extensive-stage small cell lung cancer than either one alone.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer or Other Solid Tumors

    This phase II trial studies how well talazoparib works in treating patients with breast cancer (BRCA)1 and BRCA2 wild-type (lacking an inherited form of the BRCA1 or BRCA2 gene mutation), triple-negative (estrogen receptor-, progesterone receptor-, and HER2-negative) breast cancer or other solid tumors with faulty deoxyribonucleic acid repair mechanisms or HER2-negative breast cancer with evidence of a hereditary breast cancer syndrome or evidence of genetic changes in the tumor tissue that has come back or spread to other places in the body. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

    This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Talazoparib in Treating Patients with Advanced Solid Tumors and BRCA Mutations

    This pilot phase I / II trial studies the action and how well talazoparib works in treating patients with breast cancer mutations and solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers

    This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Talazoparib and Irinotecan Hydrochloride with or without Temozolomide in Treating Younger Patients with Refractory or Recurrent Solid Malignancies

    This phase I trial studies the side effects and best dose of talazoparib when given with irinotecan hydrochloride with or without temozolomide in treating younger patients with solid malignancies that do not respond to treatment or have come back after a period of time during which the cancer could not be detected. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether talazoparib and irinotecan hydrochloride work better when given with or without temozolomide in treating younger patients with refractory or recurrent solid malignancies.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of talazoparib when given together with carboplatin and paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib with carboplatin and paclitaxel may kill more tumor cells.
    Location: 3 locations